Abeona Therapeutics Inc. and Ann & Robert H. Lurie Children’s Hospital of Chicago announced on May 14, 2025, that Lurie Children’s is now activated as the first Qualified Treatment Center (QTC) for ZEVASKYN™ (prademagene zamikeracel) gene-modified cellular sheets. This marks a significant step in the commercial availability of ZEVASKYN, the first and only cell-based gene therapy for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Lurie Children’s Hospital has completed all necessary QTC start-up activities.
The activation enables the hospital to begin identifying patients for ZEVASKYN treatment, with the first patient expected to be biopsied in July 2025 and receive treatment in August 2025. ZEVASKYN is the only FDA-approved product to treat RDEB wounds with a single application, offering durable healing and pain reduction. This commercial launch milestone underscores the collaborative efforts to bring this groundbreaking therapy to patients.
Abeona has also deployed its comprehensive patient support program, Abeona Assist™, to help eligible patients and their families navigate the treatment journey, including insurance benefits, financial assistance, and logistical support. The opening of this first QTC is a critical step in making ZEVASKYN accessible to the RDEB community across the U.S.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.